Robert Barrow

Robert Barrow discloses dealings in Definium Therapeutics, Inc. to SEC (Form 4). The record holds 45 filings, for trades running from 15 January 2022 to 25 September 2026.

In open-market terms, that means 2 purchases worth €5,596 on one side and 30 sales worth €3.6M on the other. The totals do not cover 1 filing with an undisclosed amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 13 share grants. In 2026 alone, the filings show no purchases and 4 sales.

The latest filing, published on 29 September 2026, reports an open-market sale of €1.0M in Definium Therapeutics, Inc. The latest purchase dates back some time: it was published 789 days ago, on 20 August 2024. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.